This course focuses on antimicrobial stewardship as an approach to address healthcare-associated infections (HAI) resulting from multi-drug resistance organisms in acute care settings.
Since the most recent ECDC rapid risk assessment in 2021, the number of EU/EEA countries reporting hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23 has increased from four to ten and the number of cases reported to ECDC by the countries, increased from 12 to 143.
This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
In 2022, 30 EU/EEA countries reported 4 149 confirmed cases of shigellosis. Of those cases with information available on travel history, 48% were associated with travel.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 December 2023 and includes updates on cholera, SARS-CoV-2 variant classification, avian influenza in fur farms, hepatitis A, pertussis, a cluster of extensively drug-resistant Shigella Sonnei among men who have sex with men, and an overview of respiratory virus epidemiology in the EU/EE.
Haemophilus influenzae type b (Hib) is an obligate human pathogen and an important cause of invasive bacterial infections in both children and adults, with the highest incidence among young children.
A joint study of the National Public Health Organization in Greece (NPHO) and the European Centre for Disease Prevention and Control (ECDC) conducted in 15 Greek hospitals in 2022 sheds light on the rapid spread of carbapenemase-producing, highly drug-resistant Klebsiella pneumoniae sequence type (ST) 39, following its initial documentation in a European-wide genomic survey in 2019.
The main aim of the genomic study described in this surveillance report was to determine the distribution of the highly drug-resistant clade of Klebsiella pneumoniae (sequence type (ST) 39 in Greek hospitals in 2022.